Developing a new generation of highly selective and potent kinase therapies to dramatically improve the lives of patients with genomically defined diseases

Blueprint Medicines (NASDAQ: BPMC) is developing a new generation of targeted and potent kinase medicines to improve the lives of patients with genomically defined diseases. Its approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. Blueprint Medicines is advancing four programs in clinical development for subsets of patients with gastrointestinal stromal tumors, hepatocellular carcinoma, systemic mastocytosis, non-small cell lung cancer, medullary thyroid cancer and other advanced solid tumors, as well as multiple programs in research and preclinical development.

Year Invested: 2011
Location: Cambridge, Mass.

Recent News

March 14, 2018
Blueprint Medicines to Present Proof-of-Concept Data from Ongoing Phase 1 Clinical Trial of BLU-667 in Patients with RET-Altered Solid Tumors in a Clinical Trials Plenary Session at AACR Annual Meeting 2018

March 6, 2018
Blueprint Medicines to Present at Cowen and Company 38th Annual Health Care Conference

February 21, 2018
Blueprint Medicines Reports Fourth Quarter and Full Year 2017 Financial Results

Read More News

Associated Team Members

Neil Exter

Alexis Borisy